Header Logo

Connection

MICHAEL JAMES OVERMAN to Administration, Intravenous

Back to Details
This is a "connection" page, showing publications MICHAEL JAMES OVERMAN has written about Administration, Intravenous.
MICHAEL JAMES OVERMAN
Connection Strength
0.161
Administration, Intravenous
  1. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. J Immunother Cancer. 2020 02; 8(1).
    View in: PubMed
    Score: 0.161
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.